CA3193961A1 - Reprogrammable iscb nucleases and uses thereof - Google Patents

Reprogrammable iscb nucleases and uses thereof

Info

Publication number
CA3193961A1
CA3193961A1 CA3193961A CA3193961A CA3193961A1 CA 3193961 A1 CA3193961 A1 CA 3193961A1 CA 3193961 A CA3193961 A CA 3193961A CA 3193961 A CA3193961 A CA 3193961A CA 3193961 A1 CA3193961 A1 CA 3193961A1
Authority
CA
Canada
Prior art keywords
iscb
composition
domain
activity
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3193961A
Other languages
English (en)
French (fr)
Inventor
Han ALTAE-TRAN
Soumya KANNAN
Fatma Esra DEMIRCIOGLU
Feng Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Broad Institute
Original Assignee
Massachusetts Institute of Technology
Broad Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Broad Institute filed Critical Massachusetts Institute of Technology
Publication of CA3193961A1 publication Critical patent/CA3193961A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
CA3193961A 2020-10-23 2021-10-22 Reprogrammable iscb nucleases and uses thereof Pending CA3193961A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063105191P 2020-10-23 2020-10-23
US202063105177P 2020-10-23 2020-10-23
US63/105,191 2020-10-23
US63/105,177 2020-10-23
US202163156857P 2021-03-04 2021-03-04
US63/156,857 2021-03-04
US202163195659P 2021-06-01 2021-06-01
US63/195,659 2021-06-01
US202163235583P 2021-08-20 2021-08-20
US63/235,583 2021-08-20
PCT/US2021/056361 WO2022087494A1 (en) 2020-10-23 2021-10-22 Reprogrammable iscb nucleases and uses thereof

Publications (1)

Publication Number Publication Date
CA3193961A1 true CA3193961A1 (en) 2022-04-28

Family

ID=81289497

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3193961A Pending CA3193961A1 (en) 2020-10-23 2021-10-22 Reprogrammable iscb nucleases and uses thereof

Country Status (8)

Country Link
US (1) US20230392131A1 (enExample)
EP (1) EP4203993A4 (enExample)
JP (1) JP2023546671A (enExample)
KR (1) KR20230111189A (enExample)
AU (1) AU2021364399A1 (enExample)
CA (1) CA3193961A1 (enExample)
IL (1) IL302101A (enExample)
WO (1) WO2022087494A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
US20230040216A1 (en) * 2019-11-19 2023-02-09 The Broad Institute, Inc. Retrotransposons and use thereof
CA3177051A1 (en) 2020-03-31 2021-10-07 Metagenomi, Inc. Class ii, type ii crispr systems
EP4225928A4 (en) * 2020-10-09 2025-04-30 The Broad Institute, Inc. GENETIC MODIFICATION USING A HELITRON
CN119452085A (zh) 2021-08-27 2025-02-14 宏基因组学公司 具有ruvc结构域的酶
WO2023097228A1 (en) * 2021-11-23 2023-06-01 The Broad Institute, Inc. Reprogrammable iscb nucleases and uses thereof
KR20240110603A (ko) 2021-11-24 2024-07-15 메타지노미, 인크. 엔도뉴클레아제 시스템
US20250283116A1 (en) * 2022-05-06 2025-09-11 Cornell University Use of iscb in genome editing
WO2023230483A2 (en) * 2022-05-23 2023-11-30 The Broad Institute, Inc. Engineered chimeric iscb polypeptides and uses thereof
JP2025525583A (ja) 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性ｄｎａベクター
WO2024038168A1 (en) * 2022-08-19 2024-02-22 UCB Biopharma SRL Novel rna-guided nucleases and nucleic acid targeting systems comprising such
WO2024083135A1 (en) * 2022-10-17 2024-04-25 Huidagene Therapeutics (Singapore) Pte. Ltd. Iscb polypeptides and uses thereof
WO2024094084A1 (en) * 2022-11-01 2024-05-10 Huidagene Therapeutics Co., Ltd. Iscb polypeptides and uses thereof
CN118620868A (zh) * 2023-03-07 2024-09-10 上海科技大学 IscBn-ωRNA编辑系统及其应用
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
WO2024197185A1 (en) 2023-03-21 2024-09-26 The Broad Institute, Inc. Methods and compositions for dissecting organelle physiology
WO2024206825A2 (en) * 2023-03-31 2024-10-03 Aera Therapeutics, Inc. Modified iscb nucleases, modified guide rnas, and uses thereof
WO2024220715A2 (en) * 2023-04-19 2024-10-24 Mammoth Biosciences, Inc. Effector proteins and uses thereof
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state
WO2025007044A1 (en) * 2023-06-28 2025-01-02 The University Of Chicago Methods and compositions comprising iscb variants
WO2025049788A1 (en) 2023-08-29 2025-03-06 The Broad Institute, Inc. Optical genetic screens of intracellular and intercellular transcriptional circuits with perturb-fish
EP4771154A2 (en) 2023-09-01 2026-07-08 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025096916A1 (en) 2023-11-03 2025-05-08 The Broad Institute, Inc. Multi-site editing in living cells
WO2025100980A1 (ko) * 2023-11-08 2025-05-15 한국과학기술원 Ube3a를 표적으로 하여 발현증강을 유도하는 안티센스 올리고뉴클레오티드 및 이의 용도
WO2025101679A1 (en) * 2023-11-10 2025-05-15 Mammoth Biosciences, Inc. Effector proteins and uses thereof
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025129158A1 (en) 2023-12-15 2025-06-19 The Broad Institute, Inc. Engineered arc delivery vesicles and uses thereof
WO2025149083A1 (en) * 2024-01-11 2025-07-17 Huidagene Therapeutics Co., Ltd. Iscb polypeptides and uses thereof
WO2025155923A1 (en) 2024-01-17 2025-07-24 The Broad Institute, Inc. Aav capsid modifications that enable improved cns-wide gene delivery through interactions with the transferrin receptor
WO2025160155A1 (en) 2024-01-22 2025-07-31 The Broad Institute, Inc. Epigenetic targeting of prion diseases
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025217174A1 (en) 2024-04-08 2025-10-16 The Broad Institute, Inc. Aav capsid modifications that enable improved cns-wide gene delivery through interactions with carbonic anhydrase iv
WO2025217163A2 (en) 2024-04-08 2025-10-16 The Broad Institute, Inc. Novel aav capsids binding to human cd59
WO2026107393A2 (en) 2024-11-14 2026-05-21 The Broad Institute, Inc. Aav capsid modifications that reduce immunogenicity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018035250A1 (en) * 2016-08-17 2018-02-22 The Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
US12534714B2 (en) * 2019-03-18 2026-01-27 The Broad Institute, Inc. Type VII CRISPR proteins and systems
WO2020191241A1 (en) * 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences

Also Published As

Publication number Publication date
AU2021364399A1 (en) 2023-05-11
IL302101A (en) 2023-06-01
JP2023546671A (ja) 2023-11-07
KR20230111189A (ko) 2023-07-25
EP4203993A1 (en) 2023-07-05
AU2021364399A9 (en) 2023-07-06
WO2022087494A1 (en) 2022-04-28
US20230392131A1 (en) 2023-12-07
EP4203993A4 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
US12548638B2 (en) Methods for designing guide sequences for guided nucleases
Giuliano et al. Generating single cell–derived knockout clones in mammalian cells with CRISPR/Cas9
Wang et al. The CRISPR‐Cas13a gene‐editing system induces collateral cleavage of RNA in glioma cells
Cong et al. Genome engineering using CRISPR-Cas9 system
US12221720B2 (en) Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells
US20230392131A1 (en) Reprogrammable iscb nucleases and uses thereof
Makharashvili et al. Catalytic and noncatalytic roles of the CtIP endonuclease in double-strand break end resection
JP2022176275A (ja) Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質
JP2022081522A (ja) がん免疫療法のためのｃｒｉｓｐｒ－ｃａｓ関連方法、組成物および構成要素
RU2766685C2 (ru) Рнк-направляемая инженерия генома человека
CA3106035A1 (en) Cas12b enzymes and systems
CA3064601A1 (en) Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
Ioannidi et al. Drag-and-drop genome insertion without DNA cleavage with CRISPR-directed integrases
US20240318165A1 (en) Type i-b crispr-associated transposase systems
EA038500B1 (ru) Термостабильные нуклеазы cas9
JP2016528894A (ja) ゲノムエンジニアリング
US20220380758A1 (en) Type i-b crispr-associated transposase systems
CN109072258A (zh) 复制型转座子系统
Steyer et al. High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells
Wang et al. CRISPR-Cas9 HDR system enhances AQP1 gene expression
EP4271805A1 (en) Novel nucleic acid-guided nucleases
Chen et al. Structure‐guided engineering of a Cas12i nuclease unlocks near‐PAMless genome editing
CN109957570A (zh) 靶向编辑bcr-abl融合基因的gRNA序列及其应用
Takagi et al. Comprehensive analysis of end-modified long dsDNA donors in CRISPR-mediated endogenous tagging
Termglinchan et al. Efficient genome editing in induced pluripotent stem cells with engineered nucleases in vitro

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241018

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241018

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241018

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251017

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251017

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251022

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251022

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251022

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251222

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251222

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251222

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251222

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251222

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260122